InSysBio CEO Oleg Demin gives a talk at the 6th FIP Pharmaceutical Sciences World Congress2017

events
Conference
May 23, 2017

Moscow, Russia - May 23, 2017. InSysBio CEO Oleg Demin gives a talk at the 6th FIP Pharmaceutical Sciences World Congress2017. He will speak about how to use QSP modeling to investigate drug safety at different stages of development.

Oleg will describe two case studies from the InSysBio practice in his report. The first one concerns Familial Mediterranean Fever (FMF) therapy, which is being developed by R-Pharm pharmaceutical company (Russia). A new drug, which is a protein that binds several mediators of the disease, is now undergoing clinical trials. R-Pharm provided data on preclinical studies on monkeys, and the task of the InSysBio team was to predict the minimal effective dose for human trials, which means striking a balance between efficacy and safety. You will learn from Oleg Demin's presentation how the InSysBio team met this challenge with the help of systems pharmacology tools.

The second case shows how QSP modeling helped to explain the mechanisms of eosinophilia in patients receiving a specific anti-asthma therapy.It is known that an increase in the number of blood eosinophils under asthma pathology is a marker of inflammation. Therefore drugs causing a similar effect were considered not to be safe. However, with the help of system pharmacology modeling, the group led by Tatyana Karelina showed that the substance was not only safe but also effective, and eosinophilia in blood was a consequence of a decrease in inflammation in lungs. You can read more about this case here.

At the end of his report Oleg will present the latest InSysBio scientific developments. He will talk about cutting-edge modeling methods for immunological diseases and medications. In this field it is very dangerous to choose the wrong dose or target: several cases of patients’ deaths at the first stages of clinical trials are known. That's why pharmaceutical companies need to get exact predictions for immune drug development. Come and listen to Oleg's speech about methods for cell dynamics modeling in immunology May 24, 2017 on section Systems pharmacology – innovative approaches to drug safety, Stockholm, Sweden.

September 2024
MoTuWeThFrSaSu
      
1
2
3
4
1. 04 Sep 2024 16:07 Now B cells model reflects the current views on the processes InSysBio launches Immune Response Template (IRT) version 3.6.3. IRT represents a QSP platform of immune system, simultaneously, being a tool for development of models related to immune system
5
6
7
8
9
10
1. 10 Sep 2024 18:36 InSysBio team to publish the new article in PSPJournal The new article "Quantitative systems pharmacology model of α-synuclein pathology in Parkinson's disease-like mouse for investigation of passive immunotherapy mechanisms" by Olga Ivanova and Tatiana Karelina was published in PSPJournal at the end of August 2024
11
1. 11 Sep 2024 15:25 InSysBio to take part in ACoP 2024 InSysBio announces its participation in the 15th American Conference on Pharmacometrics (ACoP). Oleg Demin Jr, Scientific Director, Oncology & Immuno-Oncology, will be a co-chair and speaker of the session "Advancing QSP: From Virtual Patient To Digital Twin". InSysBio team is going to present its modeling services & software to optimize drug development at the Booth #11 and 9 posters in frames of the Conference
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
      
Upcoming Events
Tags
Latest News
10.09
InSysBio team to publish the new article in PSPJournal
04.09
InSysBio to launch Immune Response Template version 3.6.3 for QSP modeling
22.02
14th InSysBio’s Annual Internal Scientific Meeting
24.01
InSysBio to present the new Plugin for Sublime Text and Heta compiler Online
07.12
InSysBio to release public beta of fIVE Calculator